Panion reports successful safety study in dogs
Panion Animal Health AB develops a unique new gene therapy treatment for dogs with epilepsy. In spring 2018, a safety study in dogs was started under the lead of Associate Professor David Woldbye, Department of Neuroscience, University of Copenhagen. The clinical phase of the study is now finalised, and the first preliminary outcome can be reported.
All treated dogs have successfully completed the study without observable adverse reactions. Neurological examination of the dogs before and after the treatment showed no related changes, and the dogs exhibited ordinary behavior shortly after the gene therapy treatment procedure.
“We are extremely satisfied with the conduct and clinical results of the study. The observations confirm the good results that we have seen in earlier preclinical studies in
rats and dogs.” says CEO Anja Holm, “The many laboratory tests and samples will now be handled and analysed, and we expect that they support the direct observations. When a detailed report is ready in a couple of months, we will inform the market again.”
The positive results from the safety study paves the way for conducting clinical trials in privately owned dogs that suffer from drug-refractory epilepsy. 1-2 % of all dogs worldwide have epilepsy and a third of these are not well controlled with medication. Panion’s new gene therapy product is intended to cover the therapeutic gap for such dogs and their caring owners.
This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion’s CEO, Anja E. H. Holm, for publication on August 30 2018.
Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.